Compounding BPC-157: A regulatory loophole In a statement, Health Canada said "BPC157 has not been authorized, its safety, efficacy, and quality have not been assessed and there is limited scientific evidence to support its use, including a lack of established human dosing protocols." In addition, the regulator says BPC-157 is not approved for use in any NHPs in any form, including oral and injectable, but it can still be compounded for topical use or oral administration as an NHP
For shipping purposes, maybe consider adding additional ice packs
Misconception: Topical GHK-Cu is as effective as injectable transdermal penetration of peptides is limited by molecular size (GHK-Cu = 340.84 Da, near the upper limit for passive diffusion)
For a complete understanding of NAD+ biology and its role in aging, see our NAD+ complete guide
Will Kirby holds a degree in Biology from Emory University and earned his medical degree from Nova Southeastern University
Ready to embark on your wellness journey